These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 15521841

  • 1. A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis.
    Sterling RK, Salvatori JJ, Luketic VA, Sanyal AJ, Fulcher AS, Stravitz RT, Contos MJ, Mills AS, Shiffman ML.
    Aliment Pharmacol Ther; 2004 Nov 01; 20(9):943-9. PubMed ID: 15521841
    [Abstract] [Full Text] [Related]

  • 2. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses.
    van Hoogstraten HJ, Wolfhagen FH, van de Meeberg PC, Kuiper H, Nix GA, Becx MC, Hoek AC, van Houte DP, Rijk MC, Salemans JM, Scherpenisse J, Schrijver M, Smit AM, Spoelstra P, Stadhouders PH, Tan TG, Hop WC, ten Kate FJ, vanBerge-Henegouwen GP, Schalm SW, van Buuren HR.
    J Hepatol; 1998 Sep 01; 29(3):417-23. PubMed ID: 9764988
    [Abstract] [Full Text] [Related]

  • 3. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series.
    Schramm C, Schirmacher P, Helmreich-Becker I, Gerken G, zum Büschenfelde KH, Lohse AW.
    Ann Intern Med; 1999 Dec 21; 131(12):943-6. PubMed ID: 10610645
    [Abstract] [Full Text] [Related]

  • 4. Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis.
    Stiehl A.
    Ital J Gastroenterol; 1996 Apr 21; 28(3):178-80. PubMed ID: 8789831
    [Abstract] [Full Text] [Related]

  • 5. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis.
    Wolf JM, Rybicki LA, Lashner BA.
    Aliment Pharmacol Ther; 2005 Nov 01; 22(9):783-8. PubMed ID: 16225486
    [Abstract] [Full Text] [Related]

  • 6. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.
    Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW.
    Gastroenterology; 2001 Oct 01; 121(4):900-7. PubMed ID: 11606503
    [Abstract] [Full Text] [Related]

  • 7. Bile acids for primary sclerosing cholangitis.
    Poropat G, Giljaca V, Stimac D, Gluud C.
    Cochrane Database Syst Rev; 2011 Jan 19; 2011(1):CD003626. PubMed ID: 21249655
    [Abstract] [Full Text] [Related]

  • 8. Bile acids for primary sclerosing cholangitis.
    Chen W, Gluud C.
    Cochrane Database Syst Rev; 2003 Jan 19; (2):CD003626. PubMed ID: 12804480
    [Abstract] [Full Text] [Related]

  • 9. Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.
    Talwalkar JA, Angulo P, Keach JC, Petz JL, Jorgensen RA, Lindor KD.
    J Clin Gastroenterol; 2005 Feb 19; 39(2):168-71. PubMed ID: 15681915
    [Abstract] [Full Text] [Related]

  • 10. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
    Boberg KM, Schrumpf E.
    Tidsskr Nor Laegeforen; 1997 Sep 30; 117(23):3370-3. PubMed ID: 9411890
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Sclerosing cholangitis with granulocytic epithelial lesion: a benign form of sclerosing cholangiopathy.
    Zen Y, Grammatikopoulos T, Heneghan MA, Vergani D, Mieli-Vergani G, Portmann BC.
    Am J Surg Pathol; 2012 Oct 30; 36(10):1555-61. PubMed ID: 22982898
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid.
    Rudolph G, Kloeters-Plachky P, Rost D, Stiehl A.
    Eur J Gastroenterol Hepatol; 2007 Jun 30; 19(6):487-91. PubMed ID: 17489059
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study.
    Stiehl A, Rudolph G, Sauer P, Benz C, Stremmel W, Walker S, Theilmann L.
    J Hepatol; 1997 Mar 30; 26(3):560-6. PubMed ID: 9075663
    [Abstract] [Full Text] [Related]

  • 18. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period.
    Stiehl A, Walker S, Stiehl L, Rudolph G, Hofmann WJ, Theilmann L.
    J Hepatol; 1994 Jan 30; 20(1):57-64. PubMed ID: 8201224
    [Abstract] [Full Text] [Related]

  • 19. Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone.
    Rabahi N, Chrétien Y, Gaouar F, Wendum D, Serfaty L, Chazouillères O, Corpechot C, Poupon R.
    Gastroenterol Clin Biol; 2010 Jan 30; 34(4-5):283-7. PubMed ID: 20417047
    [Abstract] [Full Text] [Related]

  • 20. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis.
    Charatcharoenwitthaya P, Angulo P, Enders FB, Lindor KD.
    Hepatology; 2008 Jan 30; 47(1):133-42. PubMed ID: 17992695
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.